A total of 83 patients were evaluated and positivity for PD-1, PD-L1 in the tumor, and PD-L1 in the TIL was seen in 51.8%, 15.7%, and 13.3%, respectively (Table 1, Figs. 3 and 4). This evidence concerns the gene PDCD1 and neoplasm.